Pancreatic Cancer Therapeutics & Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

Treatment is the fastest growing sector, North America is the largest market

The Global Pancreatic Cancer Therapeutics & Diagnostics Market is projected to grow from USD 4.72 Billion in 2025 to USD 7.31 Billion by 2031, at a 7.56% CAGR. This market includes pharmaceutical treatments like chemotherapies and targeted immunotherapies, alongside advanced imaging and molecular biomarker assays for disease identification and staging.

Growth is structurally driven by an expanding geriatric population and the rising global prevalence of lifestyle-related risk factors such as type 2 diabetes and obesity, necessitating increased oncological interventions. However, a significant obstacle is the persistent late-stage diagnosis, which severely limits treatment efficacy and curative surgical options for most patients. The asymptomatic nature of early-stage disease leads to poor prognoses and a restricted patient pool for new therapies, underlined by a critically low 13% five-year relative survival rate in 2025, according to the American Cancer Society, highlighting substantial clinical gaps.

Market Drivers

The primary structural catalyst for market expansion is the increasing global incidence and prevalence of pancreatic cancer, demanding urgent advancements in clinical management. As populations age and lifestyle risk factors like obesity and diabetes become more widespread, the number of patients requiring oncological intervention has steadily grown, driving demand for diagnostic screenings and therapeutic regimens. For example, the American Cancer Society reported an estimated 67,440 new cases in the United States alone in January 2025, emphasizing the critical need for scalable medical solutions.

Simultaneously, the market is being transformed by novel immunotherapies and targeted therapeutic agents, shifting treatment paradigms from conventional chemotherapies towards precision oncology. Pharmaceutical pipelines increasingly leverage specific biomarkers for improved patient outcomes, with a notable breakthrough being the 83% overall response rate achieved by avutometinib and defactinib in metastatic pancreatic ductal adenocarcinoma patients, as highlighted by Verastem Oncology in May 2025. These therapeutic strides are complemented by innovations in detection, such as the FDA's breakthrough device designation for DAMO PANDA, an AI-powered model for pancreatic cancer detection, signaling a parallel commitment to enhancing early-stage diagnosis and survival prospects.

Market Challenges

A significant restriction on the commercial scalability of the Global Pancreatic Cancer Therapeutics & Diagnostics Market is the persistent challenge of late-stage diagnosis. Since the disease typically progresses without specific symptoms until metastasis, most patients are ineligible for curative surgical interventions upon identification. This delay shifts the primary clinical focus from long-term disease management to short-term palliative care, drastically compressing the therapeutic window.

Consequently, sustained administration of pharmaceutical agents is hindered, reducing the total drug volume dispensed per patient compared to other chronic oncology indications. This rapid clinical decline severely limits the addressable patient pool needed for high-volume market growth. The high attrition rate means eligible patient populations for novel therapies turn over quickly, preventing developers from accumulating a stable revenue base. This trend is underscored by the narrow gap between incidence and mortality, with an estimated 51,980 pancreatic cancer deaths in the United States in 2025, according to the American Cancer Society, which directly dampens overall market valuation by making it difficult to maintain viable patient cohorts for extended regimens.

Market Trends

The emergence of KRAS-targeted therapeutic agents represents a pivotal shift in treating pancreatic ductal adenocarcinoma, specifically addressing mutations previously considered undruggable. While earlier efforts focused on rare G12C mutations, recent clinical progress has successfully targeted the more prevalent G12D variant, offering new hope for refractory cases. This trend moves beyond broad-spectrum chemotherapy to directly silence the oncogenic driver, establishing a precise mechanism of action for a larger patient subset.

A notable advancement was reported by VJOncology in October 2025, where investigational KRAS G12D inhibitors demonstrated overall response rates of 30% to 50% in pre-treated patients, signifying a major leap in precision oncology and potentially a new standard of care. Simultaneously, the proliferation of liquid biopsy and blood-based biomarkers is fundamentally altering the diagnostic landscape by enabling non-invasive, early-stage detection.

This trend addresses the critical need for screening tools that can identify malignancy before metastasis, significantly expanding the curative window. Developers are leveraging multi-analyte assays combining mRNA signatures with advanced algorithms for unprecedented accuracy, as exemplified by Mainz Biomed's proprietary PancAlert test achieving 100% sensitivity and 95% specificity in distinguishing pancreatic cancer patients from healthy controls in October 2025. Such high-fidelity diagnostics are essential for shifting market value from palliative management to curative interventions, driving long-term growth through increased surgical eligibility and survivorship.

Key Market Players

• Myriad Genetics Inc.
• Pfizer Inc.
• Novartis AG
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• Amgen Inc.
• Viatris Inc.
• Boston Scientific Corporation
• FUJIFILM Holdings Corporation
• Canon Inc.
• Rafael Holdings Inc

Report Scope

In this report, the Global Pancreatic Cancer Therapeutics & Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pancreatic Cancer Therapeutics & Diagnostics Market, by Type:

• Treatment
• Diagnostics

Pancreatic Cancer Therapeutics & Diagnostics Market, by End-User:

• Hospital & Clinic
• Ambulatory Centers
• Others

Pancreatic Cancer Therapeutics & Diagnostics Market, by Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pancreatic Cancer Therapeutics & Diagnostics Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.